The Italian board for the Tailored Biologic therapy (ITABIO) reviewed the most consistent literature to indicate the best strategy for the second-line biologic choice in patients with RA, SpA, and psoriatic arthritis PsA.
Second line biologic therapy is preferred for patients suffering from rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). The presented systematic review focuses on anti-tumor necrosis factor (TNF) therapy as criteria to comparatively analyze the efficacy of different second line biologic therapies in the treatment of RA, spondyloarthritis (SpA), and PsA. The severity of psoriasis and the predominance of enthesitis and/or dactylitis may drive the choice toward ustekinumab or secukinumab in PsA, and the latter in AS.
Osteoarthritis (OA) of the knee is a common, nonfatal, chronic condition that causes pain and physical disability in older people. Persons with knee OA report difficulty with activities that require ambulation and transfer from sitting to standing position. Exercise interventions, especially muscle strengthening therapies can potentially benefit the patients suffering from acute pain and instability associated with osteoarthritis (OA). The present systematic review assessed if the increase of 30% in knee strength is associated with the improvement in illness and disability in OA patients.
To analyze if exercise interventions for patients with knee osteoarthritis (OA) following the American College of Sports Medicine (ACSM) definition of muscle strength training differs from other types of exercise, and to analyze associations between changes in muscle strength, pain, and disability.
Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody used for the treatment of severe to moderate rheumatoid arthritis. Tocilizumab (TCZ) can improve the patient and physician measures of disease activity and it remains unaffected by the serological status of rheumatoid arthritis (RA) patient.
Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody used for the treatment of severe to moderate rheumatoid arthritis.
Breast cancer treatment often leads to neuropathic pain which results in deterioration of the sleep quality; however, evidences for this finding are not fully discovered. The study presented here is based on the understanding of sleep impairment associated with neuropathic pain occurring in the first year after the diagnosis of breast cancer.
Data regarding the impact of breast cancer treatment-related neuropathic pain (NP) on sleep quality are scarce.
Sevoflurane is a potential anesthetic used in pediatric patients, but its administration can lead to agitation in children. However, this agitation can be minimized with the help of medications.
Sevoflurane is often used in pediatric anesthesia and is associated with high incidence of psychomotor agitation.
- 1 of 102